REG - Trellus Health PLC - Business update

Trellus HealthAnnouncement

04/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250304:nRSD1826Za&default-theme=true

RNS Number : 1826Z  Trellus Health PLC  04 March 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Business update

 

LONDON, U.K. AND NEW YORK, U.S. (4 March 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, provides a business update.

 

In September 2024, within Trellus Health's interim results, the Company stated
its cash runway had been extended into late Q3 2025. As of 28 February 2025,
the Company had net cash of $3.4 million, with the Company's current cash
runway extending to the end of October 2025, on current contracted revenue
levels.

 

In January 2025
(https://www.londonstockexchange.com/news-article/TRLS/agreement-with-johnson-johnson/16850506)
, the Company announced it had entered into an agreement with Johnson &
Johnson Health Care Systems Inc. ("J&J") to support a pilot in the US to
assess the potential for the Trellus Elevate program to support patients with
moderately to severely active inflammatory bowel disease (IBD). The one-year
collaboration will provide eligible patients prescribed J&J therapy access
to Trellus Elevate. The Company is collaborating closely with J&J to
finalise preparations for the program launch.

 

In Trellus Health's interim results in September 2024
(https://www.londonstockexchange.com/news-article/TRLS/half-year-report/16684365)
, the Company announced that the enrollment phase of its
business-to-business-to-consumer ("B2B2C") agreement signed with a large US
national health plan had been extended. The enrollment phase has now
concluded, with the program now closed to new members. Whilst, as previously
announced, the number of enrolled members is limited, positive outcomes from
these members have been seen. For those who participated, there was an 89%
increase in resilience-associated behaviour upon completion of the program,
and 78% reported feeling more confident about managing their condition at
three months. Trellus Health will continue to service those members active on
the platform until the earlier of either the completion of the term of the
contract in November 2025 or until all current members have completed their
personal resilience program.

 

In Trellus Health's interim results in September 2024, the Company also
referenced two licensing agreements with pharmaceutical industry partners for
elements of its resilience-based methodology. One agreement is for the use of
resilience-based assessments in the setting of a clinical trial and the other
is for the use of customised self-efficacy educational content. These
agreements have generated modest revenue as expected and, along with the
J&J collaboration, highlight the potential value of the Company's
proprietary resilience-based platform, programs and assessments to pharma
clients.

 

The Company remains focused on demonstrating commercial progress and pursuing
potential partnership agreements, particularly within its pharmaceutical
verticals, to enhance patient support for approved therapies and to support
clinical trials where low resilience contributes to higher attrition rates and
extended completion timelines.

 

The Company will provide its full year results for the year ending 31 December
2024 no later than 30 June 2025 and provide further updates to the market in
due course as appropriate.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "We
kicked off 2025 with the signing of a key pilot agreement with J&J and
have made significant progress on implementation in preparation for launch.
The pharmaceutical sector remains a core strategic focus for us, as we believe
our resilience-based methodology delivers meaningful value to both our
partners and individuals managing chronic conditions. We are working hard to
achieve further commercial and strategic progress and will provide further
updates to the market in due course as appropriate."

 

For further information please contact:

 

 Trellus Health plc                                                 https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder         Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)              Tel: +44 (0)20 7496 3000
 Jen Boorer / James Todd / Jalini Kalaravy

 Walbrook PR                        Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                    (mailto:trellus@walbrookpr.com)
 Paul McManus / Phillip Marriage /  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082/

 Louis Ashe-Jepson                  +44 (0) 7747 515 393

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSSIESDEISESD